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Abstract
Objectives: Mortality in pancreatic cancer has remained unchanged over the last 20–30 years. The aim
of the present study was to analyse survival trends in a selected population of patients submitted to
resection for pancreatic cancer at a single institution.
Methods: Included were 544 patients who underwent pancreatectomy for pancreatic cancer between
1990 and 2009. Patients were categorized into two subgroups according to the decade in which resection
was performed (1990–1999 and 2000–2009). Predictors of survival were analysed using univariate and
multivariate analyses.
Results: Totals of 114 (21%) and 430 (79%) resections were carried out during the periods 1990–1999
and 2000–2009, respectively (P < 0.0001). Hospital length of stay (16 days versus 10 days; P < 0.001) and
postoperative mortality (3% versus 1%; P = 0.160) decreased over time. Median disease-specific survival
significantly increased from 16 months in the first period to 29 months in the second period (P < 0.001).
Following multivariate analysis, poorly differentiated tumour [hazard ratio (HR) 3.1, P < 0.001], lymph node
metastases (HR = 1.9, P < 0.001), macroscopically positive margin (R2) resection (HR = 3.2, P < 0.0001),
no adjuvant therapy (HR = 1.6, P < 0.001) and resection performed in the period 1990–1999 (HR = 2.18,
P < 0.001) were significant independent predictors of a poor outcome.
Conclusions: Longterm survival after surgery for pancreatic cancer significantly improved over the
period under study. Better patient selection and the routine use of adjuvant therapy may account for this
improvement.
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Introduction
Pancreatic ductal adenocarcinoma (PDA) remains one of the
most challenging and deadly malignancies, with 5-year overall
survival of < 5%.1 In 2012, it was estimated that 43 920 patients
would be diagnosed and 37 390 would die of pancreatic cancer in
the USA.2 Total cancer mortality rates in the USA and the EU
demonstrated a trend towards improved survival towards the end
of the 20th century.3 Moreover, declines in mortality continued
throughout the first decade of the 21st century in such malignan-
cies as gastric, colorectal, breast, uterus and prostate cancers and
leukaemia, and in lung cancer in men.4 Despite these remarkable
improvements in outcomes in most neoplasms, survival rates in
pancreatic cancer have remained stable during the same time
period. No improvements in relative survival in PDA have
occurred since the 1970s and most patients are found to have
metastatic or locally advanced disease at diagnosis and are thus
not suitable for surgical resection.5–8 The only measurable
improvement has been observed in patients with localized disease
and reflects an increased surgical resection rate.9,10 The main
reason for this improvement refers to the earlier diagnosis of small
and localized tumours, mainly as a result of the widespread use of
high-quality imaging techniques.11 Furthermore, as pancreatic
surgery has become safer, and mortality and morbidity rates more*These authors share senior authorship.
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acceptable, indications for surgical resection for PDA have been
extended to older patients and to those with more preoperative
morbidities to a greater extent than in the past.12 For patients with
localized disease, the improvement in survival parallels that seen
in high-volume centres. Several studies have correlated periopera-
tive outcomes with hospital volume of pancreatic surgeries, dem-
onstrating that pancreatectomy performed at a high-volume
centre improves outcomes as measured by perioperative mortality
and hospital length of stay (LoS).13–16 Other experiences have
demonstrated the correlation of hospital volume with longterm
survival after pancreatectomy.17,18
The aim of the present study was to analyse survival trends in
patients subjected to pancreatectomy for PDA over the past two
decades in a high-volume institution.
Materials and methods
The prospective pancreatic cancer database maintained at the
Department of Surgery, University of Verona Hospital, was
queried. Between 1990 and December 2009, 544 patients with
histologically proven PDA underwent pancreatic resection.
Demographics, clinical data, operative details and pathological
data were retrieved and analysed.
Surgery
Pancreatic resection was performed according to the site of
disease. Briefly, tumours located in the head, neck or uncinate
process of the pancreas were treated with pancreaticoduodenec-
tomy (PD), whereas neoplasms localized in the pancreatic body or
tail were treated with distal pancreatectomy and splenectomy. A
total pancreatectomy was performed in patients with multifocal
tumours or in the presence of multiple frozen sections with posi-
tive margins. Since 1998, pylorus-preserving PD has been the
procedure of choice for pancreatic head tumours whenever feasi-
ble. A standard lymphadenectomy routinely comprised clearance
of the peripancreatic nodes and of lymph nodes located in the
hepatoduodenal ligament, behind the bile duct and the portal vein
and along the hepatic artery. The operating surgeon’s decision on
whether or not to extend lymphadenectomy was determined
mainly by the presence of suspicious nodes other than those rou-
tinely resected (i.e. coeliac axis nodes, inter-aorto-cava and pre-
aortic nodes, intestinal nodes). All operations were performed
directly by or under the supervision of an experienced pancreatic
surgeon. Intraoperative frozen-section examination of transec-
tion margins was routinely performed; when positive margins
were identified, the resection was extended to a total pancreatec-
tomy if necessary. Postoperative mortality and morbidity were
considered within a month or when either event occurred during
the index hospitalization.
Pathology
The pathological protocol required an initial macroscopic evalu-
ation with recognition of all surgical margins (pancreatic, biliary,
duodenal, gastric), as well as the retroperitoneal margin. This
latter margin (the fibrotic tissue between the pancreas and the
superior mesenteric artery) was coloured in India ink prior to
1996. Specimens were then fixed in formalin and microscopically
examined in their entirety through mapping. Tumour, node and
grading were assessed. Grading was scored as G1 (well differenti-
ated), G2 (moderately differentiated) or G3 (poorly differenti-
ated). All patients were restaged according to the 2010 American
Joint Committee on Cancer (AJCC) classification.19 The quality of
resection was determined according to the R classification defined
by the International Union Against Cancer (R0 = no residual
tumour; R1 = all identifiable tumour removed, but neoplastic cells
are present at 1 mm from any surgical margin; R2 = tumour left
macroscopically in situ).
Medical therapy
Until 1996, adjuvant treatment was not routinely offered. Between
1997 and 2006, most patients were enrolled and randomized into
various ongoing trials (ESPAC-1 and then ESPAC-3).20,21 Begin-
ning in 1997, the main reasons for the non-administration of
adjuvant therapywere: (i) randomization in theobservation armof
the ESPAC-1 trial, and (ii) insufficient or late (8 weeks) recovery
after surgery. Borderline tumours as defined by Katz et al.22 were
reviewed for neoadjuvant therapy. All patients were monitored at
3-month intervals using imaging studies and laboratory tests.
Failure sites were recorded only when visible at imaging and clas-
sified as local, distant or both.Follow-upwas updated in June 2011.
Statistical analysis
Continuous variables are reported as medians and interquartile
ranges (IQRs) (25th and 75th percentiles). Categorical variables
are presented as numbers and percentages. Comparisons between
subgroups were carried out using the Mann–Whitney U-test for
continuous variables. Qualitative data were compared using the
chi-squared test or Fisher’s exact test as appropriate. Patients were
categorized into two subgroups according to the decade in which
they underwent resection (1990–1999 and 2000–2009). Disease-
specific survival (DSS) was defined as the time from diagnosis to
disease-related death and was censored at the last follow-up date if
no event had occurred.
Disease-specific survival data were computed using the
Kaplan–Meier method and the curves compared using the log-
rank test. Univariate and multivariate analyses were performed by
the Cox regression model to evaluate significant mortality predic-
tors. All factors possibly related to disease-specific death were
included in the multivariate model. Survival analysis was carried
out for the entire cohort, as well as for 1-year survivors. A separate
analysis of 1-year survival was performed to minimize confound-
ing factors such as improvements in postoperative mortality and
patient selection. Statistical analyses were performed in spss
Version 16.0 (SPSS, Inc., Chicago, IL, USA). A P-value of  0.05
was considered to indicate statistical significance.
HPB 959
HPB 2013, 15, 958–964 © 2013 International Hepato-Pancreato-Biliary Association
Results
Over the 20-year time period, 544 pancreatic resections were per-
formed for ductal adenocarcinoma of the pancreas. Overall, 114
(21%) resections were carried out between 1990 and 1999, and 430
(79%) between 2000 and 2009 (P < 0.001). Demographics and
clinical data are provided in Table 1.Neither patient demographics
nor major clinical findings changed significantly between the two
periods. Similar frequencies of incidentally discovered tumours
were identified in the two decades (P = 0.587).Operative details are
listed in Table 2. Table 3 summarizes pathological findings.
Survival analysis
The median follow-up was 23.5 months (IQR: 13.5–40.0
months). Disease-specific survival in the entire cohort is
depicted in Fig. 1. Median DSS significantly increased from 16
months in the first period to 29 months in the second period
(P < 0.001) (Fig. 2). Independent factors associated with poor
survival are shown in Table 4. The exclusion of patients who
died within the first year following surgery showed there to be
78 (68%) 1-year survivors in the 1990s and 370 (86%) in the
2000s (P < 0.001). Median DSS in 1-year survivors increased
between the decades from 21 months (IQR: 8–40 months) to
Table 1 Main clinical and laboratory characteristics in 544 patients submitted to surgical resection for pancreatic ductal adenocarcinoma by
period of surgery
Variable 1990–1999 (n = 114) 2000–2009 (n = 430) P-value
Gender, n (%) 0.265
Male 70 (61%) 239 (56%)
Female 44 (39%) 191 (44%)
Age > 60 years, n (%) 58 (51%) 259 (60%) 0.594
Presenting symptoms, n (%) 0.453
No 14 (12%) 63 (15%)
Yes 100 (88%) 367 (85%)
Biliary stenting, n (%) 29 (25%) 150 (34%) 0.030
CEA> 3 ng/ml, n (%) 46 (40%) 166 (39%) 0.734
CA 19-9> 36 U/ml, n (%) 92 (81%) 294 (68%) 0.010
CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9.
Table 2 Operative details in 544 patients submitted to surgical resection for pancreatic ductal adenocarcinoma by period of surgery
Variable 1990–1999 (n = 114) 2000–2009 (n = 430) P-value
Operative time, min, median (IQR) 360 (300–420) 320 (280–360) 0.120
Type of surgical resection, n (%) < 0.001
Whipple procedure 56 (49%) 25 (6%)
Pylorus-preserving procedure 34 (30%) 325 (76%)
Distal pancreatectomy 23 (20%) 65 (15%)
Total pancreatectomy 1 (1%) 15 (3%)
Venous vascular resection, n (%) 0.845
No 109 (94%) 404 (93%)
Yes 5 (6%) 26 (7%)
Length of stay, days, median (IQR) 16 (8–20) 10 (8–13) < 0.001
Postoperative mortality, n (%) 3 (3%) 5 (1%) 0.160
Postoperative morbidity, n (%) 46 (40%) 158 (37%) 0.501
Specific complications, n (%)
Pancreatic fistula 17 (15%) 71 (17%) 0.680
Abdominal collection 11 (10%) 45 (11%) 0.719
DGE syndrome 3 (3%) 17 (4%) 0.468
Reoperation 7 (6%) 18 (4%) 0.441
Bleeding 6 (5%) 23 (5%) 0.908
IQR, interquartile range; DGE, delayed gastric emptying.
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43 months (IQR: 21–55 months) (P < 0.001). No differences
emerged between the periods in terms of frequency of R1 resec-
tion (P = 0.694) or tumour grading (P = 0.859) in 1-year sur-
vivors. The percentage of 1-year survivors who underwent
adjuvant treatment was significantly higher in 2000–2009 than
in 1990–1999 (80% versus 44%; P < 0.001).
Discussion
This study demonstrates that longterm survival after surgery for
pancreatic cancer significantly improved over the study time
period (1990–2009).Most population-based studies have failed to
demonstrate any significant improvement in longterm survival
Table 3 Pathological findings in 544 patients submitted to surgical resection for pancreatic ductal adenocarcinoma by period of surgery
Variable 1990–1999 (n = 114) 2000–2009 (n = 430) P-value
Tumour size, mm, median (IQR) 30 (20–40) 25 (20–30) 0.001
Resection margin, n (%) 0.311
R0 75 (66%) 265 (62%)
R1 26 (23%) 127 (30%)
R2 13 (11%) 38 (9%)
Nodal status, n (%) < 0.001
N0 50 (44%) 81 (19%)
N+ 64 (56%) 349 (81%)
Number of nodes, median (IQR) 9 (6–18) 23 (16–31) < 0.001
Lymph node ratio, n (%) 0.060
0 < LNR< 0.05 3 (5%) 49 (14%)
0.05 < LNR < 0.2 24 (39%) 142 (42%)
LNR> 0.2 35 (56%) 147 (43%)
Tumour grading, n (%)
G1 4 (4%) 25 (6%) 0.345
G2 70 (61%) 259 (61%)
G3–4 40 (35%) 138 (32%)
Adjuvant therapy, n (%) 41 (36%) 336 (78%) < 0.001
Neoadjuvant therapy, n (%) 0 42 (10%) < 0.001
IQR, interquartile range; LNR, lymph node ratio.
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Figure 1 Disease-specific survival shown as a Kaplan–Meier curve
for the entire cohort (n = 544) of patients with pancreatic cancer who
underwent resection at the study institution during 1990–2009
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Figure 2 Disease-specific survival shown in Kaplan–Meier curves
in patients operated during 1990–1999 (n = 114) and 2000–2009
(n = 430), respectively (P < 0.0001, log-rank comparison)
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among patients with pancreatic cancer.5–8 Survival trends in these
studies are related mainly to high frequencies of patients with
locally advanced or metastatic disease, and the only measurable
improvement in survival has been observed for tumours diag-
nosed at an earlier stage.9,10
The current study shows that rates of incidentally discovered
tumours did not change over the study time period, whereas
median tumour size decreased. This reflects improvements in
high-quality imaging techniques during the last decade and, in
particular, the widespread use of computed tomography (CT).
Cross-sectional imaging is crucial to correct staging. Multiphase,
multidetector helical CT with i.v. administration of contrast
medium is currently the procedure of choice for the initial evalu-
ation of pancreatic cancer.23 The value of this diagnostic tool refers
to its facility to enable visualization of the primary tumour in
relation to the superior mesenteric artery, coeliac axis, superior
mesenteric vein and portal vein with an accuracy of 80–90%.24
Analysis of the current data demonstrates a reduction in carbo-
hydrate antigen 19-9 (CA 19-9) values in the second period of the
study.This is likely to relate to evidence published in the last decade
about the clinical usefulness of CA 19-9 as a prognostic marker.25,26
More accurate patient selection by radiological staging and labo-
ratory evaluation partially explains the improvement in longterm
survival seen in the current study. The high-volume centre repre-
sents an independent predictor of postoperative mortality after
pancreatic surgery.13 In the present series, rates of postoperative
mortality and perioperative complications remained constant over
time. Despite no changes in postoperative complications, hospital
LoS was significantly reduced in the latter period of the study. This
is congruous to the data reported by Winter et al.27 and Balcom
et al.28 and probably reflects the implementation of clinical path-
ways, and earlier oral feeding and drain removal during the latter
period.29 On the basis of the current results, the value of using an
experienced centre seems to relate to the centre’s expertise in
managing complications rather than its ability to prevent them.
To limit the effect of confounding variables such as postopera-
tive mortality and early diagnosis, data for those patients who
survived were analysed. The current study showed that 1-year
survivors operated in the later period achieved better survival.
These results contrast with those reported by Winter and
co-workers,30 who reported similar rates of longterm survival
across three decades in 1-year survivors treated at the Memorial
Sloan–Kettering Cancer Center (MSKCC). Two main reasons may
account for this discrepancy infindings.Firstly, in the current series
all patients with borderline tumours underwent chemotherapy or
chemoradiation rather than upfront surgery. Moreover, arterial
resection has shown no survival benefit in patients with pancreatic
cancer.31 In theMSKCC study,30 the inclusion of patients subjected
to arterial resection may have biased the results and worsened
longterm outcomes. Secondly, Winter et al.30 did not report the
overall use of adjuvant therapy because a considerable number of
patients were treated and followed by local medical oncologists. In
the current study, adjuvant therapy was mainly offered in the
second period of the study according to the study institution’s
participation in two different trials.20,21 In the current analysis,
receipt of adjuvant chemotherapywas identified as an independent
predictor of survival after pancreatectomy for pancreatic cancer.At
present, there have been six prospective and randomized trials
comparing surgery with adjuvant therapy and surgery alone in
patients with pancreatic cancer.32 A significant improvement in
overall survival with adjuvant therapy was achieved in three of the
six trials. A meta-analysis examined five randomized adjuvant
trials and found that adjuvant chemotherapy conferred a 3-month
survival benefit.32 Nevertheless, in the present study, time of
surgery emerged as an independent predictor of DSS [hazard ratio
(HR) 2.184]. It is likely that survival increased in the second decade
of the period under study for multiple reasons, including: (i) the
provision of amore accurate preoperative diagnosis; (ii) improved
postoperativemanagement and decreased perioperativemortality,
and (iii) better patient selection for surgical resection. However, it
remains concerning that 20–30% of resected patients can be
expected to die of disease within 12 months of resection, even if
adjuvant therapy is delivered.33 In the present authors’ experience,
highpreoperative levels of CA19-9, longdurationof symptoms,R2
resection and the presence of G3 neoplasms were found to be
independent predictors of early death.33 Itmight be speculated that
as these parameters have been recognized preoperatively in recent
years, even in the setting of resectable disease, a neoadjuvant
approach rather than upfront surgery should be considered.This is
supported by the observation that rates of pain and elevated serum
levels of CA 19-9 in patients undergoing surgical resection were
Table 4 Multivariate analysisa of factors associated with disease-
specific survival after surgery for pancreatic ductal adenocarcinoma
Variable HR 95% CI P-value
Adjuvant therapy
Yes 1 – –
No 1.602 1.264–2.030 < 0.001
Grading
G1 1 – –
G2 2.153 1.171–3.956 < 0.001
G3-4 3.170 1.705–5.894 < 0.001
Nodal status
N0 1 – –
N+ 1.959 1.500–2.559 < 0.001
Resection margin
R0 1 – –
R1 1.730 1.374–2.179 < 0.001
R2 3.285 2.377–4.540 < 0.001
Date of operation
2000–2009 1 – –
1990–1999 2.184 1.688–2.825 < 0.001
aAdjusted for gender and age.
HR, hazard ratio; 95% CI, 95% confidence interval.
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significantly lower in the second time period (2000–2009).
However, other unknown variables may have positively affected
survival in the more recent period. Indeed, it is possible that
improvements in palliative treatments and end-of-life care may
have influenced longterm survival.
In conclusion, a slight but significant improvement in longterm
survival after pancreatectomy for resectable pancreatic cancer has
been achieved in the last decade. Better patient selection accounts
for the improvement in early survivorship. The improvement in
longterm survival possibly relates to the routine use of adjuvant
therapy, as well as other factors such as the introduction of best
care when recurrence eventually occurs.
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